Clinical Trial Update: Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the safety and efficacy of activated recombinant human factor VII for treating bleeding in patients following allogeneic ste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Bleeding Disorder
• Bleeding During After Surgery

Drugs mentioned

• Activated Recombinant Human Factor VII (Factor VIIa)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Acquired Bleeding Disorder, Bleeding During/Following Surgery | Phase 2 | Status: COMPLETED